TrialStudy of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Trial details
- Registry ID
- NCT03608033
- Phase
- Phase 3
Drug research
Vehicle (D5W or saline)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033 | Omeros Corporation | Phase 3 | Terminated | 2024-01-12Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |